Rivoceranib
- Generic Name
- Rivoceranib
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C24H23N5O
- CAS Number
- 811803-05-1
- Unique Ingredient Identifier
- 5S371K6132
- Background
Rivoceranib is under investigation in clinical trial NCT02726854 (Apatinib as Second-line Treatment of Advanced Pancreatic Cancer).
- Indication
本品单药适用于既往至少接受过2种系统化疗后进展或复发的晚期胃腺癌或胃-食管结合部腺癌患者。患者接受治疗时应一般状况良好。
- Associated Conditions
- -
- Associated Therapies
- -
The Maintenance Treatment of Apatinib/Capecitabine Versus Observation in Advanced Gastric Cancer
- First Posted Date
- 2019-03-26
- Last Posted Date
- 2019-03-26
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 242
- Registration Number
- NCT03889626
Neoadjuvant Immunotherapy for Resectable Gastric Cancer
- Conditions
- Interventions
- First Posted Date
- 2019-03-18
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- Qilu Hospital of Shandong University
- Target Recruit Count
- 25
- Registration Number
- NCT03878472
- Locations
- 🇨🇳
Qilu hospital of Shandong univertisy, Jinan, Shandong, China
SHR-1210 in Combination With Apatinib in Patients With Metastatic, Persistent, or Recurrent Cervical Cancer
- Conditions
- Interventions
- First Posted Date
- 2019-01-25
- Last Posted Date
- 2023-04-11
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 45
- Registration Number
- NCT03816553
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
🇨🇳The First affiliated Hospital of Sun Yat-sen University, Guanzhou, Guangdong, China
🇨🇳Guangzhou Panyu Central Hospital, Guangzhou, Guangdong, China
A Study to Evaluate SHR-1210 in Combination With Capecitabine + Oxaliplatin Sequenced by SHR-1210 + Apatinib as First-line Therapy in Treatment of Advanced Gastric Cancer
- Conditions
- Interventions
- First Posted Date
- 2019-01-23
- Last Posted Date
- 2024-11-08
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 885
- Registration Number
- NCT03813784
- Locations
- 🇨🇳
Beijing Cancer Hospital, Peking University, Beijing, Beijing, China
Apatinib Combined With Radiotherapy in Patient With BM From Drive Gene Negative NSCLC
- First Posted Date
- 2019-01-11
- Last Posted Date
- 2022-02-08
- Lead Sponsor
- Hubei Cancer Hospital
- Target Recruit Count
- 90
- Registration Number
- NCT03801200
- Locations
- 🇨🇳
Hubei Cancer hospital, Wuhan, Hubei, China
A Trial of SHR-1210 in Combination With Apatinib in Patients With Unresectable HCC
- First Posted Date
- 2019-01-04
- Last Posted Date
- 2019-01-04
- Lead Sponsor
- Yanqiao Zhang
- Target Recruit Count
- 30
- Registration Number
- NCT03793725
Pemetrexed Plus Apatinib Maintenance Treatment in Patients With Non-squamous Non-small Cell Lung Cancer Patients Who Have Not Progressed After 4 Cycles of Induction Chemotherapy of Pemetrexed in Combination With Platinum-based Regimen
- Conditions
- Interventions
- First Posted Date
- 2019-01-03
- Last Posted Date
- 2024-02-28
- Lead Sponsor
- Xinqiao Hospital of Chongqing
- Registration Number
- NCT03792503
- Locations
- 🇨🇳
Xinqiao Hospital of Chongqing, Chongqing, China
Apatinib Combined With POF for Second-line Treatment of Gastric Adenocarcinoma
- First Posted Date
- 2018-12-27
- Last Posted Date
- 2019-05-10
- Lead Sponsor
- Fujian Cancer Hospital
- Target Recruit Count
- 26
- Registration Number
- NCT03788174
- Locations
- 🇨🇳
Rongbo Lin, Fuzhou, China
A Study of Second-line Treatment of Postoperative Recurrence and Metastasis of Esophageal Cancer Treated With Apatinib
- Conditions
- Interventions
Phase II Study of SHR-1210(Anti-PD-1 Antibody) Combination With Apatinib Versus Pemetrexed and Carboplatin in Subjects With KRAS Mutant Stage IV Non-squamous Non-small Cell Lung Cancer
- First Posted Date
- 2018-12-17
- Last Posted Date
- 2019-01-18
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 230
- Registration Number
- NCT03777124
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.